Neointima Contribution to Haemostasis of Polyester Vascular Grafts
The aim of the study. Assessment of dynamic changes in the expression of activators and inhibitors of coagulation and fibrinolysis in the neointima of polyester vascular grafts during their healing process.
Material and methods. The study was carried out on 18 dogs that underwent replacement of infrarenal abdominal aorta with a polyester DALLON - double velour prosthesis. Grafts were removed after 1, 4 and 12 months and fixed according to the AMeX method. Immunohistochemical labeling for tissue factor (TF), tissue factor pathway inhibitor (TFPI), tissue plasminogen activator (t-PA), urokinase plasminogen activator (u-PA), plasminogen activator inhibitor type-1 (PAI-1), prothrombin activation fragment F1+2 (F1+2) and D-dimer (DD) was performed on the neointima of the grafts.
Results. TF expression did not demonstrate any significant differences in all study periods. TFPI expression appeared at 4 months and was increased at 12 months. Intensive F1+2 expression was shown at 1 month; its mild expression was still present in the following periods of the study. Plasminogen activators were demonstrated at 1 month and their expression was increased at 4 and 12 months, whereas weak expression of PAI-1 and DD was shown in all study periods.
Conclusions. High thrombotic potential of polyester vascular graft neointima is present in all periods of the graft healing process. Increasing TFPI and plasminogen activators expression in the late postoperative follow-up favors graft patency maintenance.
Handt S, Jerome WG, Tietze L et al.: Plasminogen activator inhibitor-1 secretion by endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: evidence for a key role of endothelial cells in thrombolytic resistance. Blood 1996; 87: 4204-13.
Hursting MJ, Slaughter TF, Stead AG et al.: Standardization of prothrombin fragment 1.2 measurement: effects of preanalytical variables and calibrator selection. Arch Pathol Lab Med 1998; 122: 31-36.
Gosselin RC, Owings JT, Utter GH et al.: A new method for measuring D-dimer using immunoturbidometry: a study of 255 patients with suspected pulmonary embolism and deep vein thrombosis. Blood Coagul Fibrinolysis 2000; 11: 715-21.
Kowalewski R, Zimnoch L, Wojtukiewicz MZ et al.: Coagulation activators and inhibitors in the neointima of polyester vascular grafts. Blood Coagul Fibrinolysis 2003; 14: 433-39.
Harvey RA, Kim HC, Pincus J et al.: Binding of tissue plasminogen activator to vascular grafts. Thromb Haemost 1989; 61: 131-36.
Kitamoto Y, Tomita M, Kiyama S et al.: Antithrombotic mechanisms of urokinase immobilized polyurethane. Thromb Haemost 1991; 65: 73-76.
Kowalewski R, Zimnoch L, Wojtukiewicz MZ et al.: Expression of fibrinolysis activators and their inhibitor in neointima of polyester vascular grafts. Biomaterials 2004; 25: 5987-93.
Sasajima T, Takano Y, Hiraishi Y et al.: High accumulation of plasminogen and tissue plasminogen activator at the flow surface of mural fibrin in the human arterial system. J Vasc Surg 2000; 32: 374-82.
Kauhanen P, Siren V, Carpen O et al.: Plasminogen activator inhibitor -1 in neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure. Circulation 1997; 96: 1783-89.
Głowiński S, Worowski K: Distribution and variation of thromboplastic and fibrinolytic activity of dacron aortic grafts. Cor Vasa 1979; 21: 296-303.
Oltrona L, Eisenberg PR, Abendschein DR et al.: Efficacy of local inhibition of procoagulant activity with small-diameter prosthetic grafts. J Vasc Surg 1996; 24: 624-31.
Toursarkissian B, Eisenberg PR, Abendschein DR et al.: Thrombogenicity of small-diameter prosthetic grafts: relative contribution of graft-associated thrombin and factor Xa. J Vasc Surg 1997; 25: 730-35.
Sato Y, Mukai K, Watanabe S et al.: The AMeX method. A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am J Pathol 1986; 125: 431-35.
Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Hist Cytochem 1981; 29: 577-80.
Sirén V, Kauhanen P, Carpén O et al.: Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis. Blood Coagul Fibrinolysis 2003; 14: 369-77.
Głowiński S, Worowski K: Porównanie aktywności składników układu hemostatycznego warstwy wewnętrznej przeszczepów DALLON - standard i dwustronny welur. Pol Przegl Chir 1990; 62: 915-21.
Głowńnski S, Worowski K: Thromboplastic and fibrinolytic activity of autogenous - free vein grafts used as abdominal aorta replacements in dogs. Haemostasis 1980; 9: 167-74.
Rumisek JD, Wade CE, Kaplan K et al.: The influence of early surface thromboreactivity on longterm arterial graft patency. Surgery 1989; 105: 654-61.
Lemson SM, Tordoir JHM, Daemen MJAP et al.: Intimal hyperplasia in vascular grafts. Eur J Vasc Surg 2000; 19: 336-51.
Mitra AK, Gangahar DM, Agrawal DK: Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia. Immunol Cell Biol 2006; 84: 115-24.
Sato Y, Asada Y, Marutsuka K et al.: Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 1996; 75: 389-92.
Sato Y, Asada Y, Marutsuka K et al.: Tissue factor pathway inhibitor inhibits aortic smooth musc le cell migration induced by tissue factor/factor VIIa complex. Thromb Haemost 1997; 78: 1138-41.
Xiaoli M, Wenying H, Mingpeng S: Effects and mechanism of tissue-type plasminogen activator and plasminogen activator inhibitor on vascular smooth muscle cell proliferation. Int J Cardiol 1998; 66 (suppl. 1): S57-S64.
Østerud B, Bajaj MS, Bajaj SP: Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. Thromb Haemost 1995; 73: 873-75.
Schecter AD, Spirn B, Rossikhina M et al.: Release of active tissue factor by human arterial smooth muscle cells. Circ Res 2000; 87: 126-32.
Raybagkar DA, Patchipulusu S, Mast AE et al.: In vitro flow evaluation of recombinant tissue factor pathway inhibitor immobilized on collagen impregnated Dacron. ASAIO J 2004; 50: 301-05.
Rubin BG, Toursarkissian B, Petrinec D et al.: Preincubation of Dacron graft with recombinant tissue factor inhibitor decreases their thrombogenicity in vivo. J Vasc Surg 1996; 24: 865-70.
Clowes AW, Clowes MM, Au YP et al.: Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-67.
Gasic GP, Arenas CP, Gasic TB et al.: Coagulation factors X, Xa and protein S as mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 1992; 89: 2317-20.
McNamara CA, Sarenbock IJ, Gimple LW et al.: Thrombin stimulates proliferation of aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993; 91: 94-98.
Sun LB, Utoh J, Moriyama S et al.: Pretreatment of a Dacron graft with tissue factor pathway inhibitor decreases thrombogenicity and neointimal thickness: a preliminary animal study. ASAJO J 2001; 47: 325-28.
Quax PHA, Pedersen N, Masucci MT et al.: Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regulation 1991; 2: 793-803.
Urayama H, Katada S, Kasashima F et al.: Rupture of pseudointima in an implanted vascular prosthesis: immunohistological study of plasminogen activators and matrix metalloproteinases. J Cardiovasc Surg 2000; 41: 459-62.